Oncology & Cancer

The role of fibronectin in BRAF-mutant thyroid cancer treatment

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene—a mutation also ...

Oncology & Cancer

Study identifies strategy to avoid resistance to cancer therapy

Resistance to therapies is one of the obstacles to overcome in cancer treatments. Understanding the mechanisms of this resistance is essential to design strategies that favor tumor cell death. A study led by the Protein Kinases ...

Oncology & Cancer

Boosting immunotherapy in non-responsive cancer cells

Cancer immunotherapy primes a patient's immune system to better find and destroy cancer cells, improving upon the body's natural ability to fight tumors. Contemporary immunotherapy approaches aim to stimulate immune cells ...

page 2 from 40